Substance Misuse

March 12, 2026 | Fact Sheets, Psychedelics, Substance Misuse

Amanita muscaria is a psychoactive mushroom with a bright red cap covered in white spots or warts that is native to the temperate and boreal forests of the northern hemisphere. A. muscaria mushrooms are also called “fly agaric” mushrooms due to their traditional use as an insecticide. Though A. muscaria is a psychoactive mushroom, it is not a classic psychedelic like the mushrooms of the Psilocybe genus, which are commonly referred to as “magic mushrooms.” The renewed interest in psilocybin-containing mushrooms in the 21st century due to their potential use in treating various mental and physical health conditions has sparked consumers’ interest in other types of mushrooms, including A. muscaria, that are more legally accessible. As A. muscaria use increases, there have been public health concerns regarding unregulated sales of A. muscaria products and the lack of consumer knowledge about how A. muscaria differs from psilocybin containing mushrooms. This fact sheet addresses those issues....

February 27, 2026 | Controlled Substances, Harm Reduction, Model Laws, Recovery, Substance Misuse, Substance Use Disorder

The Model Addressing Drug Diversion in Healthcare Settings Act (1) requires healthcare entities to establish policies and procedures for the prevention and detection of drug diversion by healthcare professionals and to ensure that treatment and recovery support services are offered to eligible healthcare professionals; (2) requires certain individuals and entities to report healthcare professionals suspected of misusing drugs and/or alcohol, diverting drugs for personal use, having an untreated substance use disorder, or practicing while impaired and to establish penalties for failure to make such reports; (3) requires boards, as defined in this Act, to establish or participate in an alternative to discipline program for eligible healthcare professionals; (4) establishes legal protections for individuals who make reports as required by this Act; (5) provides immunity from civil and criminal liability for specified individuals and entities for actions taken pursuant to this Act; (6) establishes penalties for healthcare entities that fail to take corrective action after discovering diversion by a healthcare professional; (7) establishes program reporting and audit requirements; (8) establishes technology grants for healthcare entities to be used for the prevention and detection of drug diversion; and (9) establishes funding provisions for alternative to discipline programs....

February 5, 2026 | Controlled Substances, Kratom, Legal & Legislative Research, Opioids, Substance Misuse

Kratom is an herb derived from a leafy Southeast Asian tree and contains two psychoactive compounds that can bind to opioid receptors in the brain and produce a pharmacological response similar to effects produced by other opioid agonists, such as morphine. As of January 2026, 30 states and the District of Columbia regulate kratom. This document: (1) provides a singular resource for each jurisdiction’s laws; (2) allows for a comparison of these laws between jurisdictions; and (3) identifies and highlights interesting provisions....

January 23, 2026 | Controlled Substances, Innovative Initiatives, Medication Assisted Treatment (MAT), Opioids, Peer Support and Recoery Services, Prescription Drugs, Recovery, Reentry, Substance Misuse, Substance Use Disorder

Ryther, a nonprofit mental health service provider for children, teens, and young adults in Seattle, Washington, provides therapeutic services to youth struggling with mental and behavioral health issues, including substance use disorder (SUD). As part of its menu of services for SUD treatment, Ryther offers medication for addiction treatment (MAT) for those aged 12 to 25 who have opioid use disorder (OUD), making the program unique in focusing on young people. Ryther’s MAT program provides holistic treatment that addresses the physical, mental, emotional, and social challenges faced by children and young adults with SUD. Many of the participants in Ryther’s MAT program are homeless or experiencing housing instability, and the program is designed to provide these individuals with low barrier resources and support....

December 23, 2025 | Fact Sheets, Novel Psychoactive Substances, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) is monitoring the emergence of novel psychoactive substances (NPS) appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet, an UPDATE to the third in a series highlighting these potentially dangerous drugs, examines tianeptine, an unapproved drug commonly sold in gas stations and on the internet as a dietary supplement and causes opioid-like withdrawals....

December 22, 2025 | Controlled Substances, Drug Courts, First Responders, Law Enforcement, Legal & Legislative Research, Public Health, Public Safety, Substance Misuse, Treatments

All across the U.S. jails are filled with people who need medical care and social services, many of whom cycle in and out of jail without ever receiving the help they need. One emerging model to combat this problem is deflection, which seeks to prevent individuals who have low to moderate criminogenic risk, but significant unmet social, economic, and health needs, from entering the criminal justice system. The goal of deflection programs is to lessen the burden on the criminal justice system by connecting those individuals—before they enter the criminal justice system—to treatment and social services to which they might not otherwise have access. This document is designed to: (1) provide a singular resource for each jurisdiction’s deflection laws; (2) allow for a comparison of these laws between jurisdictions; and (3) identify and highlight interesting provisions....

December 22, 2025 | Controlled Substances Act, Fact Sheets, Psychedelics, Substance Misuse

Psilocybin is a chemical compound produced by more than 100 species of mushrooms, many of which belong to the genus Psilocybe, found growing around the world. Various indigenous cultures have consumed psilocybin-containing mushrooms for medical purposes and as part of spiritual ceremonies for thousands of years. In 1970, Congress enacted the Controlled Substances Act (CSA) and categorized psilocybin and other psychedelic substances as Schedule I controlled substances, which effectively stopped the research into the therapeutic effects of psilocybin for several decades. Today, psilocybin remains a Schedule I controlled substance at the federal level and it is also classified as a Schedule I controlled substance in 47 states and the District of Columbia. Despite the continued challenges of researching Schedule I controlled substances, the 21st century has brought forth a renewed interest in investigating the therapeutic potential of psilocybin....

November 19, 2025 | Controlled Substances, Drug Courts, Harm Reduction, Law Enforcement, Legal & Legislative Research, Opioids, Prescription Drugs, Public Health, Public Safety, Substance Misuse

Psilocybin is a chemical compound produced by more than 100 species of mushrooms found growing around the world. Because of the psychedelic effects that these mushrooms produce when consumed, psilocybin-containing mushrooms have been colloquially referred to as “magic mushrooms” or “shrooms.” In this document, the Legislative Analysis and Public Policy Association (LAPPA) identifies both currently-in-force statutes/regulations and recently proposed legislation related to psilocybin throughout all 50 states, the District of Columbia, and the U.S. territories....

November 18, 2025 | Controlled Substances, Innovative Initiatives, Peer Support and Recoery Services, Recovery, Reentry, Substance Misuse, Substance Use Disorder, Workforce Development

In 2022, Frank Taylor, co-owner of Taylor Made Farm, a farm in Lexington, Kentucky for elite racehorses, pioneered the idea of opening the farm to men in need of substance use recovery to start their journey to long-term recovery by learning to take care of the farm’s million-dollar horses. He partnered with Christian Countzler, an Army veteran, to open Stable Recovery, a substance use disorder recovery program that combines peer recovery and 12-step program participation with horsemanship. ...